SHARE

OXIS International, Inc. (OTCMKTS:OXIS)’s subsidiary Oxis Biotech, Inc. announced that Cassian Yee, M.D., joined company’s scientific advisory board. Dr. Yee is a Professor at Department of Immunology, and also at Department of Melanoma Medical Oncology.

The profile

OXIS International subsidiary disclosed that Dr. Yee was Professor at Division of Oncology and a Member in the Department of Immunology. He attained his medical degree from the very popular University of Manitoba based in Canada. He started with research fellowship at the Ontario Cancer Institute based in Toronto and then opted for medical residency at Stanford University.

The details

OXIS International subsidiary further revealed that Dr. Yee concluded his and postdoctoral research studies and fellowship in medical oncology at the Fred Hutchinson Cancer Research Center and the University of Washington. He was awarded the prestigious Investigator Award from Cancer Research Institute, as well as Clinical Investigator award from the Damon Runyon Walter Winchell.

The momentum

Few months ago, OXIS International disclosed that it intends to up-list the stock on NASDAQ platform. Investors considered the announcement as a reason to start buying, and eventually it pushed the stock price all the way to a new 52-week high of $0.07. Sadly, the hype was short-lived and the stock price soon found declining towards $0.03. It consolidated during the next few weeks but now, people seem to be interested in buying stock once again.

The momentum

There is no press release of NASDAQ listing around and the company is not even the fastest moving OTC stock. Still, it has been recording consecutive green sessions since the beginning of May. As per the last annual report, the company had cash of $855,000 and current assets of $882,000.

In last trading session, the stock price of OXIS surged more than 2% to close the trading session at $0.0330. The gain came at a share volume of 3.50 million compared to average share volume of 4.93 million.

SHARE
Previous articleKollagenX Corp (OTCMKTS:KGNX) Extends Distribution Into New Areas
Next articleWhat Is The Buzz Surrounding Advanced Medical Isotope Corp. (OTCMKTS:ADMD)?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.

LEAVE A REPLY